FDA clears ProQR's IND to start clinical trial of QR-421a in usher syndrome type 2 patients

|About: ProQR Therapeutics (PRQR)|By:, SA News Editor

ProQR Therapeutics N.V. (NASDAQ:PRQR) announces that the FDA has cleared the IND application for QR-421a.

QR-421a is an investigational RNA-based oligonucleotide designed to address the underlying cause of the vision loss associated with Usher syndrome type 2 and non-syndromic retinitis pigmentosa (RP) due to mutations in exon 13 of the USH2A gene.

QR-421a has received orphan drug designation in U.S. and the European Union.

Subscribe for full text news in your inbox